Dr. Reddy’s Laboratories profitability dwindles in Q1FY17

Dr. Reddy’s Laboratories has declared its Q1FY17 results. The company’s revenue has declined by 14.24 per cent to Rs 3223 crore in Q1FY17 on a yearly basis. Its EBITDA has dropped by 81 per cent to Rs 190 crore in Q1FY17 as compared to same period in previous fiscal. Dr. Reddy’s Laboratories’ net profit also has dropped by more than 75 per cent to Rs 154 crore in Q1FY17 on a yearly basis.

On segmental revenue front, Dr. Reddy’s Laboratories has earned about 18.66 per cent from Pharmaceutical services & Active Ingredients and 78.31 per cent from Global Generics, 1.84 per cent from proprietary products and 1.18 per cent from others in Q1FY17.

On geographical revenue front, Dr. Reddy’s Laboratories has earned 49.98 per cent from North America, 11.01 per cent from Europe, 17.3 per cent from India and 18.57 per cent from Rest of the World during Q1FY17.

Dr. Reddy’s Laboratories has received USFDA's, 2 ANDAs and has launched the two molecules: Zembrace Sym Touch injection and Sernivo Spray in the US.

The share price of Dr. Reddy’s Laboratories has decreased by 4.37 per cent on bourses and closed at Rs 3322.85 on an intra day basis.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company that is engaged in providing medicines. The company operates in three segments viz. Global Generics; Pharmaceutical Services and Active Ingredients (PSAI); and Proprietary Products.